来自Roseburia intestinalis的细胞外囊泡通过调节肠道屏障,微生物组和炎症反应来改善结肠炎
Hwa Seung Han1,2, Soonjae Hwang2, Seung Young Choi3
1Department of Marine Bio-Food Science, Gangneung-Wonju National University, Gangneung, Republic of Korea.
Journal of extracellular vesicles
|August 21, 2024
概括
红花肠病衍生的细胞外囊泡 (R-EVs) 显示出治疗炎症性肠病 (IBD) 的潜力. 这些细菌EVs通过调节微生物群和特定的分子通路来减少肠道炎症并促进恢复.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 是一种慢性胃肠道疾病,没有确定的治疗方法.
- 肠道微生物组在IBD病原和治疗中起着至关重要的作用.
- 细菌细胞外囊泡 (BEVs) 是肠道微生物群与宿主相互作用的新兴媒介.
研究的目的:
- 为了研究Roseburia intestinalis衍生的EVs (R-EVs) 在硫酸 (DSS) 诱导的大肠炎中的治疗潜力.
- 阐明R-EVs施加抗炎作用并促进肠道恢复的机制.
主要方法:
- 使用ANCOM分析,Roseburia intestinalis被确定为一个最佳的BEV生产者.
- 使用触流过方法分离R-EV并进行了表征.
- 用DSS诱导的大肠炎模型来评估口服R-EV的有效性.
主要成果:
- 口服R-EVs在炎症的结肠组织中积累.
- R-EVs调节了肠道微生物群,增加了Bifidobacterium的丰富性.
- R-EVs抑制了结肠炎症,降低了DPP4活性,增加了活性GLP-1,并通过PI3K通路降低了NFκB和STAT3信号,从而导致肠道恢复.
结论:
- R-EVs具有强大的抗炎性质,并且在治疗DSS诱导的大肠炎方面是有效的.
- 通过调节肠道微生物群和宿主炎症途径,R-EVs代表了IBD的有希望的治疗策略.
- BEVs,特别是R-EVs,突出了IBD管理和肠道愈合的新方法.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.2K
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
817
相关概念视频
01:23Renewal of Intestinal Stem Cells
2.5K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.5K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:17Irritable Bowel Syndrome I: Introduction
264
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
264
01:29Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331